Dr. Bertino on the Impact of COVID-19 on Patients With Lung Cancer

Video

In Partnership With:

Erin M. Bertino, MD, a medical oncologist at The Ohio State University Comprehensive Cancer Center–James, discusses the potential impact of the novel coronavirus 2019 (COVID-19) on patients with lung cancer.

Erin M. Bertino, MD, a medical oncologist at The Ohio State University Comprehensive Cancer Center—James, discusses the potential impact of the novel coronavirus 2019 (COVID-19) on patients with lung cancer.

Patients with thoracic malignancies may be especially vulnerable to COVID-19 because they are also predisposed to pneumonitis and pneumonia. Additionally, these patients, some of whom are smokers, may have underlying chronic obstructive pulmonary disease and heart disease, says Bertino.

In order to reduce the risk of contracting the virus, Bertino recommends patients avoid those who are sick and large crowds until the virus can be contained. Additionally, patients who are already sick should avoid coming to the clinic to reduce the spread of the virus to other immunocompromised individuals, concludes Bertino.

Related Videos
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP